Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2016 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions

Protects Cellular Composition of Lead Immunotherapy Product Candidate ProTmune™ Covers Compositions Generated Using Ex Vivo Modulation to Enhance Stem Cell Properties SAN DIEGO, Oct. 05, 2016 ...
September 26, 2016 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell Transplantation

SAN DIEGO, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
September 07, 2016 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies

Unite Cellular Immunotherapy Expertise to Accelerate Clinical Translation of Off-the-Shelf Products Offering Broad Patient Access Collaboration to Use Engineered Pluripotent Cell Lines to...
August 31, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
August 10, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
August 08, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2016 Financial Results

Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection IND Filing for Allogeneic Memory-Like NK Cell Cancer Immunotherapy Planned for...
August 08, 2016 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces $10.3 Million Common Stock Private Placement

SAN DIEGO, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer...
August 02, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2016 Financial Results on August 8, 2016

SAN DIEGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
July 26, 2016 08:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Issuance of U.S. Patent on Compositions of Human Induced Pluripotent Cells

Key Patent Covers Renewable Pluripotent Cell Source for Development of Off-the-Shelf NK- and T-Cell Immunotherapies SAN DIEGO, July 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc....
June 20, 2016 08:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Fast Track Designation for ProTmune™

SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...